Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
about
Transgenic cell lines for detection of animal virusesNovel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesDiagnosis and management of viral retinitis in the acute retinal necrosis syndrome.Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain.Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection.Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display librariesCurrent recommendations for the treatment of genital herpes.Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementManagement of herpes simplex and varicella-zoster virus infectionsValacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.Verrucous herpes of the scrotum in a human immunodeficiency virus-positive man: case report and review of the literature.Antiviral susceptibility testing with a cell line which expresses beta-galactosidase after infection with herpes simplex virus.Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virusSurveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up.Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.The use of antiviral drugs during the neonatal periodCorrelation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients.Emerging therapies for herpes viral infections (types 1 - 8).2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2.Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responsesLongitudinal Characterization of Herpes Simplex Virus (HSV) Isolates Acquired From Different Sites in an Immune-Compromised Child: A New HSV Thymidine Kinase Mutation Associated With Resistance.Acute Liver Failure from Herpes Simplex Virus in an Immunocompetent Patient Due to Direct Inoculation of the Peritoneum.Antiviral drug resistance in herpesviruses other than cytomegalovirus.Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.Thymidine kinase mutations conferring acyclovir resistance in herpes simplex type 1 recombinant viruses.Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids.Comparative evaluation of microplate enzyme-linked immunosorbent assay versus plaque reduction assay for antiviral susceptibility testing of herpes simplex virus isolates.Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.Antiherpevirus activity of Artemisia arborescens essential oil and inhibition of lateral diffusion in Vero cells.Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.Neurovirulence and latency of drug-resistant clinical herpes simplex viruses in animal models.Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.In vitro antiviral activity of dermaseptins against herpes simplex virus type 1.Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.Evaluation of some pyrazoloquinolines as inhibitors of herpes simplex virus type 1 replication.Antiviral activity of Bifidobacterium adolescentis SPM 0214 against herpes simplex virus type 1.Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.Pseudotumour of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient.Liposome-incorporated santolina insularis essential oil: preparation, characterization and in vitro antiviral activity.
P2860
Q27477859-7FADDAA3-769A-4592-83BC-4C93BE8DDED1Q28367722-2012791B-0AA9-407A-B3CC-24DFA129E490Q33569740-908522B7-A15E-4F6E-B704-EC6B8975133DQ33804966-40FA992F-1C45-455A-9C47-B2BC8D47D0EBQ33978415-3DF167B7-AFC2-4EC9-B083-06D3AC92DC5AQ34127099-E72BC637-169D-4B42-A4D5-C2291C35F6ECQ34127423-0A211250-A69B-47ED-A0B1-132DEFA34E2FQ34149904-7A0FFC0C-FA3F-425F-A360-575BF1A9F379Q34185463-C16028CD-0BE6-414F-AF62-25929AF75F5DQ34918273-1A4BE3FE-68B3-4485-A5D0-EDAC9B4A2931Q34995157-822CCEED-9472-411E-A673-604FE25B8487Q35115200-CA581CE0-FE2A-4120-A645-935F33D2F821Q35535201-9FC8698A-61BA-43F5-B3D2-37070E3203B9Q35551858-3A85648A-47AA-4CDC-A174-69ED10A4F24CQ35641005-EC96D8FA-B50C-4A33-A0F8-56669A874162Q35789702-323B92C7-CF78-4995-8C7C-EABD96AECFFAQ35821379-45628E87-B695-44F6-BAEB-CF45EADB7C0FQ35967376-92B46A8F-D088-4461-AE06-5C86C329C1D6Q36364125-38101065-5B09-420A-85AB-8BAABF58CE88Q36478736-D6E4E426-2D62-4C36-9149-D4301014953FQ36585733-4FA12955-BD71-4134-9FE1-24A1E01624B6Q36851163-0A98DC11-505C-4E6B-963F-EB1F8CBD27AAQ37685326-EBE3D169-65BD-4093-9CA1-A8E1DCF13AF6Q38194111-5C993036-B6C2-4984-A4A1-5239E1B3B974Q38248209-4A7EB8EA-F3D9-49F7-BE91-AD5BF2BFE5C5Q39077983-20B347F7-DF8C-4CC6-AFFE-1088FC883743Q39776436-292413DE-B54A-4523-BE4F-1B2B0A9F6363Q39781894-CED30F5B-4AF6-4F90-9084-DCDC6F0F054AQ40706720-1AC02B0E-BF54-4CF6-9C3C-65E1BC7E43DEQ40810723-0E8491C7-C46C-4950-92AE-BC8E364D58CAQ40905765-EA6C65F1-CD94-4982-92AB-94B2B9358A55Q43085636-6253922E-EE84-4A79-9918-8B049A381106Q43848114-5E520EE3-1C71-4F29-B8AD-78CD1B7B9A8BQ43849033-FEF8323D-D2E6-453F-85CD-794739875540Q43938257-F59E9995-CEC4-4647-8E92-C5202CB65B80Q45286596-BF528B4D-249F-478B-8647-A4E29A8DC020Q45354401-EFC1CDEC-55C7-44D8-9C25-D9BBEE24E15DQ45361068-7F2DEB2D-A819-4E8C-9409-C44CB74B2145Q45753566-EB895D9F-6770-424C-8306-1EBA08E538A4Q45967348-A1DF229E-55C1-4A54-9225-3E40A8EF1D39
P2860
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
@en
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
@nl
type
label
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
@en
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
@nl
prefLabel
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
@en
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
@nl
P2093
P356
P1476
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
@en
P2093
De Veranez D
Kemmerly S
Weissbach N
P304
P356
10.1093/INFDIS/169.1.193
P407
P577
1994-01-01T00:00:00Z